C L Cooper1, J B Angel, I Seguin, H L Davis, D W Cameron. 1. Division of Infectious Diseases, University of Ottawa at Ottawa Hospital, Ottawa Health Research Institute, Ottawa, Canada. ccooper@ottawahospital.on.ca
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected persons are hyporesponsive to hepatitis B virus (HBV) vaccination. CPG 7909 is an oligodeoxynucleotide containing immunostimulatory CpG motifs that activate human B and plasmacytoid dendritic cells via Toll-like receptor 9. We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and longevity of the seroprotective response over 48 weeks. We now report data for the 5-year period following vaccination. METHODS: A randomized, double-blind, controlled trial was conducted to determine clinical safety and immunogenicity of HBV vaccine in adult HIV-infected subjects receiving effective antiretroviral therapy. HBV-susceptible subjects, one-half of whom had experienced previous vaccination failure, were vaccinated at 0, 1, and 2 months with a double adult dose of recombinant HBV vaccine, with or without 1 mg of CPG 7909 (19 subjects per arm). Titers of antibody to HBV surface antigen (anti-HBs) were measured at 6-month intervals for up to 60 months. RESULTS: The proportion of participants achieving and retaining seroprotection (surface antibody titers, > or =10 mIU/mL) was greater in CPG 7909 recipients (P < .05 at all time points). Geometric mean anti-HBs titers were higher in the CPG 7909 group than in the control group (without CPG 7909 adjuvant) at all measured time points. CONCLUSIONS: The immunostimulatory properties of CPG 7909 present an important strategy in achieving long-term protection in HIV-infected patients and other HBV vaccine-hyporesponsive populations.
RCT Entities:
BACKGROUND:Humanimmunodeficiency virus (HIV)-infectedpersons are hyporesponsive to hepatitis B virus (HBV) vaccination. CPG 7909 is an oligodeoxynucleotide containing immunostimulatory CpG motifs that activate human B and plasmacytoid dendritic cells via Toll-like receptor 9. We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and longevity of the seroprotective response over 48 weeks. We now report data for the 5-year period following vaccination. METHODS: A randomized, double-blind, controlled trial was conducted to determine clinical safety and immunogenicity of HBV vaccine in adult HIV-infected subjects receiving effective antiretroviral therapy. HBV-susceptible subjects, one-half of whom had experienced previous vaccination failure, were vaccinated at 0, 1, and 2 months with a double adult dose of recombinant HBV vaccine, with or without 1 mg of CPG 7909 (19 subjects per arm). Titers of antibody to HBV surface antigen (anti-HBs) were measured at 6-month intervals for up to 60 months. RESULTS: The proportion of participants achieving and retaining seroprotection (surface antibody titers, > or =10 mIU/mL) was greater in CPG 7909 recipients (P < .05 at all time points). Geometric mean anti-HBs titers were higher in the CPG 7909 group than in the control group (without CPG 7909 adjuvant) at all measured time points. CONCLUSIONS: The immunostimulatory properties of CPG 7909 present an important strategy in achieving long-term protection in HIV-infectedpatients and other HBV vaccine-hyporesponsive populations.
Authors: David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson Journal: Proc Natl Acad Sci U S A Date: 2012-03-15 Impact factor: 11.205
Authors: Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa Journal: Vaccine Date: 2015-10-26 Impact factor: 3.641
Authors: Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio Journal: Proc Natl Acad Sci U S A Date: 2014-08-18 Impact factor: 11.205